Pasithea Therapeutics (KTTA) Total Current Liabilities (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Total Current Liabilities for 4 consecutive years, with $660397.0 as the latest value for Q3 2024.
- Quarterly Total Current Liabilities fell 67.69% to $660397.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $660397.0 through Sep 2024, down 67.69% year-over-year, with the annual reading at $2.6 million for FY2023, 40.29% up from the prior year.
- Total Current Liabilities hit $660397.0 in Q3 2024 for Pasithea Therapeutics, down from $1.4 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $2.6 million in Q4 2023 to a low of $433684.0 in Q1 2022.
- Historically, Total Current Liabilities has averaged $1.5 million across 4 years, with a median of $1.5 million in 2022.
- Biggest five-year swings in Total Current Liabilities: surged 389.33% in 2023 and later crashed 67.69% in 2024.
- Year by year, Total Current Liabilities stood at $447280.0 in 2021, then soared by 319.79% to $1.9 million in 2022, then surged by 40.29% to $2.6 million in 2023, then plummeted by 74.93% to $660397.0 in 2024.
- Business Quant data shows Total Current Liabilities for KTTA at $660397.0 in Q3 2024, $1.4 million in Q2 2024, and $2.5 million in Q1 2024.